Researchers in Gastroenterology evaluated strategies for preventing avoidable colorectal cancers after colonoscopy. In ...

Incyte's experimental skin disease drug met the main goal of two separate late-stage trials, the company said on Monday, but its shares declined 11% as the drug significantly underperformed prior ...

Rinvoq (upadacitinib) is a prescription drug used to treat certain autoimmune conditions. This drug can interact with some medications, vaccines, and supplements. For example, Rinvoq can interact ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

A key regulatory win could turn this under-the-radar treatment into AbbVie's next billion-dollar success story.

RINVOQ is approved in the European Union (EU) for the treatment of adults with radiographic axial spondylarthritis, nonradiographic axial spondylarthritis, psoriatic arthritis, rheumatoid ...

A European Commission committee is recommending AbbVie's Rinvoq for treatment of giant cell arteritis following Phase 3 clinical trial results that showed efficacy and safety in the inflammatory ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults with giant cell arteritis (GCA).

The EU regulator has cleared Rinvoq (upadacitinib) as an oral treatment for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older, either with or without topical ...